Your session is about to expire
← Back to Search
Pembrolizumab for Marginal Zone Lymphoma
Study Summary
This trial is testing pembrolizumab alone or with idelalisib or ibrutinib as a treatment for relapsed or refractory chronic lymphocytic leukemia or other low-grade B-cell non-Hodgkin lymphomas.
- Marginal Zone Lymphoma
- Follicular Lymphoma
- Lymphoplasmacytic Lymphoma
- Lymphoma
- Chronic Lymphocytic Leukemia
- Non-Hodgkin's Lymphoma
- Splenic Marginal Zone Lymphoma
- Waldenstrom's Macroglobulinemia
- MALT Lymphoma
- Nodal Marginal Zone Lymphoma
- Waldenstrom Macroglobulinemia
- Richter Syndrome
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many people are part of this clinical research project?
"This particular trial is no longer recruiting patients. The listing for this clinical study was first posted on February 19th, 2015 and last updated on August 10th, 2021. There are many other active trials that may be of interest; 3889 studies are currently enrolling patients with waldenstrom macroglobulinemia and 1162 studies involve Pembrolizumab."
What types of cancer does Pembrolizumab commonly target?
"Pembrolizumab is frequently used as a treatment for patients with unresectable melanoma. It can also be effective for those with high microsatellite instability, increased risk of disease recurrence, and other similar conditions."
What other studies have been done on Pembrolizumab?
"There are 1162 total clinical trials being conducted that involve Pembrolizumab. Of these, 147 have reached Phase 3 and are still active. Although the majority of these studies originate in Houston, Texas, there are 43695 locations worldwide where research is ongoing."
Can people sign up for this clinical trial right now?
"Unfortunately, this particular trial is not currently looking for new patients to enroll. The study was initially posted on February 19th, 2015 and the most recent edit was done on August 10th, 2021. For those still exploring their options, there are 3889 other trials actively recruiting patients with waldenstrom macroglobulinemia and 1162 clinical trials involving Pembrolizumab that have open enrollment at this time."
Is Pembrolizumab known to have dangerous side effects?
"While there is some clinical data supporting the safety of Pembrolizumab, it received a score of 2 because there are no Phase 3 trials demonstrating its efficacy."
Share this study with friends
Copy Link
Messenger